Related Experiment Video
Updated: Jan 19, 2026
Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae
Published on: May 28, 2007
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for
Paul Wu1, Taymar Hartman2, Louise Almond3
1Bayer HealthCare LLC, Berkeley, CA; paul.wu@bayer.com.
Abstract:
The bioprocessing industry uses recombinant mammalian cell lines to generate therapeutic biologic drugs. To ensure consistent product quality of the therapeutic proteins, it is imperative to have a controlled production process. Regulatory agencies and the biotechnology industry consider cell line "clonal origin" an important aspect of maintaining process control. Demonstration of clonal origin of the cell substrate, or production cell line, has received considerable attention in the past few years, and the industry has improved methods and devised standards to increase the probability and/or assurance of clonal derivation. However, older production cell lines developed before the implementation of these methods, herein referred to as "legacy cell lines," may not meet current regulatory expectations for demonstration of clonal derivation. In this article, the members of the IQ Consortium Working Group on Clonality present our position that the demonstration of process consistency and product comparability of critical quality attributes throughout the development life cycle should be sufficient to approve a license application without additional genetic analysis to support clonal origin, even for legacy cell lines that may not meet current day clonal derivation standards. With this commentary, we discuss advantages and limitations of genetic testing methods to support clonal derivation of legacy cell lines and wish to promote a mutual understanding with the regulatory authorities regarding their optional use during early drug development, subsequent to Investigational New Drug (IND) application and before demonstration of product and process consistency at Biologics License Applications (BLA) submission.
Insights
Demonstrating consistent bioprocesses and comparable product quality should suffice for approving legacy cell lines, even without current clonal origin proof. This approach supports regulatory submissions for therapeutic biologic drugs.
Area of Science:
- Biotechnology and biopharmaceutical manufacturing
- Cell line development and characterization
- Regulatory science in drug development
Background:
- Recombinant mammalian cell lines are crucial for producing therapeutic biologic drugs, necessitating controlled production processes for consistent product quality.
- Clonal origin of cell substrates is a key regulatory expectation for process control, with improved methods developed for assurance.
- Legacy cell lines, developed before current clonal derivation standards, may not meet modern regulatory expectations for demonstrating clonal origin.
Purpose of the Study:
- To propose that process consistency and product comparability should be sufficient for license approval of legacy cell lines.
- To address the regulatory challenges associated with demonstrating clonal origin for older production cell lines.
- To foster mutual understanding with regulatory authorities regarding the optional use of genetic testing for legacy cell lines.
Main Methods:
- Review and discussion of genetic testing methods for supporting clonal derivation of legacy cell lines.
- Analysis of the advantages and limitations of various genetic analysis techniques.
- Examination of regulatory expectations and industry practices for cell line characterization.
Main Results:
- The article presents the position that process consistency and product comparability are adequate for approving legacy cell lines.
- Genetic testing for clonal origin is discussed as an optional tool, particularly during early drug development stages.
- The need for a balanced approach considering both historical context and current standards is highlighted.
Conclusions:
- Demonstration of process consistency and product comparability should be sufficient for license applications, even for legacy cell lines lacking current clonal derivation standards.
- Genetic analysis for clonal origin should be considered optional for legacy cell lines, especially before Biologics License Application (BLA) submission.
- A collaborative understanding between industry and regulatory agencies is needed to manage legacy cell lines effectively in biopharmaceutical development.
Related Concept Videos
15:12Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae
05:47Optimized Ex-ovo Culturing of Chick Embryos to Advanced Stages of Development
08:44The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation
07:41Clonal Genetic Tracing using the Confetti Mouse to Study Mineralized Tissues
08:15Data Communication Based on MQTT in a Polymer Extrusion Process
07:49Time-lapse Live Imaging of Clonally Related Neural Progenitor Cells in the Developing Zebrafish Forebrain